SEHK:2616Biotechs
A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Pralsetinib’s First Domestic Launch In China
CStone Pharmaceuticals (SEHK:2616) has announced the first domestically produced batch of pralsetinib capsules in China, starting nationwide distribution and leveraging National Reimbursement Drug List inclusion alongside significant year-on-year sales growth.
See our latest analysis for CStone Pharmaceuticals.
The latest product news comes after a strong run in CStone Pharmaceuticals’ stock, with the share price at HK$8.02 and a year-to-date share price return of 50.19%. The 1-year total...